MR-only prostate SABR halves penile bulb dose, but toxicity differences remain uncertain
MR-only prostate SABR reduced median penile bulb dose from 4.6 to 2.2 Gy, with lower observed urinary and sexual toxicity in nonrandomized cohorts.
MR-only prostate SABR reduced median penile bulb dose from 4.6 to 2.2 Gy, with lower observed urinary and sexual toxicity in nonrandomized cohorts.
A model using 2,485 measurements predicted lymphocyte depletion with R² 0.65; reductions ≥75% were associated with poorer three-year progression-free survival.
After a second PSMA-guided metastasis-directed RT course, 50.2% of 177 oligorecurrent prostate cancer patients remained ADT-free at two years.
Weekly cisplatin 40 mg/m² with definitive RT yielded 84% five-year survival and 80% progression-free survival in 103 p16-positive oropharyngeal cancer patients.
Among 82 cutaneous lymphoma patients, 38% prioritized quality of life, while those with Sézary syndrome traveled a median 201 km for RT.
Early tumor enlargement occurred in 14.3% with staged Gamma Knife plus bevacizumab versus 60.9% with single-session radiosurgery alone.
An editorial argues that negative phase III INTRAGO-II results strengthen the case for targeting glioblastoma biology rather than escalating radiation dose.
Among 196 prostatectomy patients, pelvic nodal salvage RT was associated with improved biochemical control in margin-negative disease, while earlier treatment predicted better outcomes.
Only 22.6% of surveyed radiation oncologists routinely offered both hippocampal avoidance and memantine, while 46.8% offered neither as standard options.
ProSpare reduced anorectal dose and showed numerically lower grade ≥1 bowel symptoms, with its primary two-year outcome still pending.
Consolidative thoracic RT was associated with median survival of 27.0 versus 15.5 months, but major treatment-selection imbalances limit interpretation.
In 77 high-risk prostate patients, five-fraction adaptive pelvic SBRT produced 6.9% late grade ≥2 GU and 9.7% GI toxicity.
In 72 matched pairs, initial local therapy without systemic treatment was associated with 73.0% versus 58.6% five-year survival, without improved PFS.
PET-detected nodal upstaging was associated with >10% PTV expansion in 48% versus 17% of patients, accompanied by increased lung exposure.
ProSpare reduced anorectal dose and showed lower grade ≥1 bowel toxicity at 18 weeks, while the trial's primary two-year endpoint remains pending.